JPRN-jRCT2080220961未知1 期
Phase I/II clinical pilot study of Hycamtin in combination with Cisplatin for extensive-disease small cell lung cancer
ippon Kayaku Co., Ltd.0 个研究点开始时间: 2010年1月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •1) Histological or cytological diagnosis of SCLC
- •2) Measurable disease
- •3) Adequate organ function
- •4) ECOG Performance Status 0-1
- •5) Life expectancy at least 3 months
- •6) Written informed consent
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial CancerNeoplasms, EndometrialEndometrial CancerNCT00267488GlaxoSmithKline70
已完成
2 期
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian CancerNeoplasms, OvarianOvarian CancerNCT00316173GlaxoSmithKline77
已完成
3 期
Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung CancerLung Cancer, Small CellNCT00276276GlaxoSmithKline141
未知
1 期
Phase I/II trial of YHI-1003 plus CapecitabineJPRN-jRCT2080221670Yakult Honsha Co.,Ltd.50
招募中
1 期
A Phase I/IIa trial of HA-Irinotecan, a formulation of hyaluronic acid and irinotecan, in the treatment of extensive stage small cell lung cancer and its effect on tumour stem cells.small cell lung cancerACTRN12611000520932Southern Health40